On August 18, XTALPI fell 5.62% in regular trading, trading at HKD 7.49 per share, with turnover of HKD 249 million.

The decline was triggered by concentrated selling pressure ahead of the company's board meeting scheduled for August 19 to review and approve interim results. The company previously issued a profit warning projecting H1 revenue of RMB 3.8-4.0 billion, down over 22% year-over-year, primarily due to a high base effect from a one-time USD 51 million pipeline licensing upfront payment recognized in the prior period. Net loss attributable to shareholders is estimated at RMB 2.15-2.75 billion, representing a swing from profit to loss. R&D expenses are expected to exceed RMB 3.4 billion, up over 50% year-over-year, reflecting intensified investment in autonomous laboratories and AI agent systems.

Sector peer Insilico Intelligence dropped 7.56% on the same day, with the broader AI-driven drug discovery segment under notable pressure. Analysts note that excluding the one-off licensing impact, core business revenue grew approximately 65% year-over-year to RMB 2.5 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)